Refractory Head and Neck atopic dermatitis pattern treated with Dupilumab: Allergic contact dermatitis caused by decyl glucoside. Should surfactants be patched?

Navarro‐Triviño, Francisco José; Vega-Castillo, Jorge Juan; Llamas‐Molina, José María; Ruiz‐Villaverde, Ricardo

doi:10.1111/ajd.13678

Cited by 3 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The differential diagnosis of facial flushing in patients with AD has been published in several articles, 11 so we will not go into detail except to emphasise the importance of patch testing in these patients to rule out allergic contact dermatitis, 12 as observed in one of our patients. In addition, the H&N pattern requires considering a differential diagnosis as well as complementary tests according to clinical suspicion 13 …”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of tralokinumab in the treatment of head and neck pattern atopic dermatitis: A multicentre study of 12 patients

Navarro‐Triviño,

Salazar‐Nievas,

Sanz‐Cabanillas

et al. 2024

Aust J Dermatology

Self Cite

View full text Add to dashboard Cite

Background/ObjectivesThe evaluation of the efficacy and safety of new molecules for atopic dermatitis (AD) in real clinical practice is very important to obtain information that clinical trials (EECC) lack. The pattern of AD in the head and neck (H&N) continues to be a challenge in treatment today, despite the new molecules, and real‐life data on the use of tralokinumab is still missing. This is the first daily practice study of tralokinumab treatment in patients with H&N AD pattern. The objective is to evaluate the efficacy and safety of tralokinumab in the short term (16 weeks) in patients with AD with H&N pattern, for the first time.MethodsA multicentre prospective observational study was conducted, including patients with moderate‐severe AD and H&N pattern who started tralokinumab treatment in four hospitals in Andalusia. Values of severity and quality of life scales, as well as patient‐reported outcomes (PROs), were collected at baseline and at Weeks 4 and 16. Safety events were also recorded.ResultsTwelve patients were included. An improvement was observed in all efficacy and quality of life parameters evaluated at 16 weeks with respect to the baseline. No serious adverse events were recorded.ConclusionsIn real clinical practice, tralokinumab is demonstrated to be an effective and safe treatment for patients with AD and H&N pattern at short term.

show abstract

Section: Discussionmentioning

confidence: 99%